Parexel Launches ParexelAI to Accelerate Clinical Trials With AI

Parexel introduced ParexelAI on May 18, 2026, consolidating its AI capabilities into a single branded suite that covers the entire clinical development lifecycle, from early-phase trial design and patient identification through regulatory submission and post-market surveillance.

The launch is not a product announcement for a new technology but a formalization of AI capabilities Parexel has been building and deploying across its operations, capabilities it is now quantifying publicly for the first time.

Site selection process timelines have been reduced by 50%. Clinical study report preparation time in medical writing has been reduced by 30%. Safety literature screening and pharmacovigilance case processing have been reduced by 20%.

"ParexelAI represents years of deep technology integration, all in service of helping our customers deliver life-changing treatments to patients," said Peyton Howell, CEO of Parexel. "We have a responsibility to continually evolve by advancing our capabilities, strengthening our partnerships and innovating in ways that help sponsors run faster, more effective trials."